<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CARTEOLOL HYDROCHLORIDE</span><br/>(car'tee-oh-lole)<br/><span class="topboxtradename">Cartrol, </span><span class="topboxtradename">Ocupress<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">beta-adrenergic antagonist (blocking agent, sympatholytic)</span>; <span class="classification">antihypertensive</span><br/><b>Prototype: </b>Propranolol<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2.5 mg, 5 mg tablets; 1% solution</p>
<h1><a name="action">Actions</a></h1>
<p>Carteolol is a beta-adrenergic blocking agent (antagonist) that competes for available beta receptor sites. It inhibits both
         beta<sub>1</sub> receptors (chiefly in cardiac muscle) and beta<sub>2</sub> receptors (chiefly in the bronchial and vascular musculature). It decreases standing and supine hypertension.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective antihypertensive agent by reducing BP to normotensive range and useful in mananging some angina, dysrhythmias, and
         CHF by decreasing myocardial oxygen demand and lowering cardiac work load.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>For hypertension, either alone or in combination with other drugs, particularly a thiazide diuretic (not indicated for hypertensive
         crisis); chronic open-angle glaucoma.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>To reduce the frequency of anginal attacks.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Sinus bradycardia, greater than first-degree heart block, cardiogenic shock, CHF secondary to tachycardia treatable with beta-blockers,
         overt cardiac failure, hypersensitivity to beta-blocking agents, persistent severe bradycardia, bronchial asthma or bronchospasm,
         and severe COPD; pregnancy (category C).
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>CHF patients treated with digitalis and diuretics, peripheral vascular disease; diabetes, hypoglycemia, thyrotoxicosis; lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2.5 mg once/d, may increase to 510 mg if needed (max: 10 mg/d)<br/><br/><span class="indicationtitle">Open-Angle Glaucoma</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Ophthalmic</span> 1 drop in affected eye b.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Consult physician if patient's creatinine clearance is below normal. Dosage adjustment may be needed.</li>
<li>Administer capsule or tablet whole. Do not crush or break and instruct patient not to chew before swallowing.</li>
<li>Store away from heat, light, or moisture.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Rash, muscle cramps, bronchospasm. <span class="typehead">CV:</span> Increased angina, hypotension, CHF, bradycardia. <span class="typehead">GI:</span> Abdominal pain, diarrhea, nausea. <span class="typehead">Endocrine:</span> Hyperglycemia. <span class="typehead">CNS:</span>
<span class="speceff-common">Headache, dizziness,</span> drowsiness, insomnia, anxiety, tremor, paresthesia, weakness. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">diuretics</span> and other <span class="classification">hypotensive agents</span> increase hypotensive effect; carteolol and <b>albuterol,</b>
<b>metoproterenol,</b>
<b>terbutaline,</b>
<b>pirbuterol</b> are mutually antagonistic; <span class="classification">nsaids</span> may blunt hypotensive effect; decreases hypoglycemic effect of <b>glyburide;</b> may increase bradycardia and sinus arrest with <b>amiodarone.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract; 85% reaches systemic circulation. <span class="typehead">Peak:</span> 13 h. <span class="typehead">Duration:</span> 2448 h. <span class="typehead">Distribution:</span> Crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver to active metabolite. <span class="typehead">Elimination:</span> Excreted primarily in urine. <span class="typehead">Half-Life:</span> 46 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Assess heart rate prior to administration. If pulse is less than 50 bpm, withhold drug and notify physician.</li>
<li>Monitor BP and pulse frequently during period of adjustment and periodically throughout therapy.</li>
<li>If hypotension (systolic BP 
         </li><li>Monitor daily weight and assess for evidence of fluid overload since drug may precipitate CHF (see Signs &amp; Symptoms, Appendix
            F).
         </li>
<li>Monitor mental status. Mental depression may be increased by use of this drug.</li>
<li>Assess respiratory status closely if the patient has history of bronchitis or emphysema, assess for respiratory difficulty.</li>
<li>Monitor diabetic for loss of diabetic control. Drug may prevent the appearance of early S&amp;S of acute hypoglycemia (see Appendix
            F).
         </li>
<li>Drug may reduce tolerance to cold temperatures in older adults or in those who have circulatory problems.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report the first sign or symptom of impending CHF (see Signs &amp; Symptoms, Appendix F) or unexplained respiratory symptoms.</li>
<li>Do not discontinue medication abruptly, since sudden withdrawal may precipitate or exacerbate angina.</li>
<li>Do not use any OTC products such as nasal decongestants and cold preparations without consultation.</li>
<li>Report slow pulse rate, confusion or depression, dizziness or light-headedness, skin rash, fever, sore throat, or unusual
            bleeding or bruising.
         </li>
<li>Be cautious while driving or performing other hazardous activities until response to drug is known.</li>
<li>Continue to take this medication as instructed by your physician no matter how well you feel.</li>
<li>Take your BP at least twice a week and report significant changes.</li>
<li>Take your pulse before and after taking the medication. If it is much slower than normal rate (or less than 50 bpm), check
            with your physician.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>